Utilization of the Tango beta-arrestin recruitment technology for cell-based EDG receptor assay development and interrogation.
Cellular assay development for the endothelial differentiation gene (EDG) family of G-protein-coupled receptors (GPCRs) and related lysophospholipid (LP) receptors is complicated by endogenous receptor expression and divergent receptor signaling. Endogenously expressed LP receptors exist in most tissue culture cell lines. These LP receptors, along with other endogenously expressed GPCRs, contribute to off-target signaling that can complicate interpretation of second-messenger-based cellular assay results. These receptors also activate a diverse and divergent set of cellular signaling pathways, necessitating the use of a variety of assay formats with mismatched procedures and functional readouts. This complicates examination and comparison of these receptors across the entire family. The Tango technology uses the conserved beta-arrestin-dependent receptor deactivation process to allow interrogation of the EDG and related receptors with a single functional assay. This method also isolates the target receptor signal, allowing the use of tissue culture cell lines regardless of their endogenous receptor expression. The authors describe the use of this technique to build cell-based receptor-specific assays for all 8 members of the EDG receptor family as well as the related LPA receptors GPR23, GPR92, and GPR87. In addition, they demonstrate the value of this technology for identification and investigation of functionally selective receptor compounds as demonstrated by the immunosuppressive compound FtY720-P and its action at the EDG(1) and EDG(3) receptors.
Wetter
Justin A
JA
Cellular Systems Division, Life technologies Corporation, Madison, Wisconsin 53706, USA. justin.wetter@Invitrogen.com
Revankar
Chetana
C
Hanson
Bonnie J
BJ
D019390:Arrestins / Q000378:metabolism*; D001681:Biological Assay / Q000379:methods*; D002460:Cell Line; D006801:Humans; D008246:Lysophospholipids / Q000378:metabolism; D010755:Organophosphates / Q000378:metabolism; D049312:Receptors, Lysophospholipid / Q000235:genetics / Q000378:metabolism; D049349:Receptors, Lysosphingolipid / Q000819:agonists / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D013110:Sphingosine / Q000031:analogs & derivatives / Q000378:metabolism; D000071557:beta-Arrestins
D019390:Arrestins; C525008:FTY 720P; D008246:Lysophospholipids; D010755:Organophosphates; D049312:Receptors, Lysophospholipid; D049349:Receptors, Lysosphingolipid; D000071557:beta-Arrestins; C060506:sphingosine 1-phosphate; D013110:Sphingosine; C032881:lysophosphatidic acid